Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point.

Journal:

Journal of the American Society of Nephrology

Published:

2025-06-18

DOI:

10.1681/asn.0000000766

Affiliations:

7

Authors:

7

Go to article

Institutions	Authors	Share
Bayer, Germany	2.000000	0.29
University Medical Center Groningen (UMCG), RUG, Netherlands	1.500000	0.21
AstraZeneca Gaithersburg, MD, United States of America (USA)	1.000000	0.14
AstraZeneca Sweden, Sweden	1.000000	0.14
AstraZeneca United States, United States of America (USA)	1.000000	0.14
The George Institute for Global Health (TGI), Australia	0.500000	0.07

Interested in Clinical Sciences?